文献速递神经免疫

在发作期与非发作期评估2023年MOGAD标准在MOG抗体阳性儿童与成人中的表现

Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks.
PubMed 文献 · Neurology · 2024-08-27

这项前瞻性观察性全国研究纳入257例血清或脑脊液MOG-IgG阳性儿童和成人,以随访>1年后的最可信诊断金标准回顾性应用2023年MOGAD标准。结果94%患者被正确分类,发作期评估准确率高于缓解期,两时期阳性预测值均高。

要点

  • 2023年MOGAD标准在儿童和成人中均正确识别大多数MOGAD患者。
  • 发作期应用标准的分类准确率高于缓解期,阳性预测值两期均高。
  • 低滴度MOG-IgG患者最终诊断为其他疾病的比例高于高滴度患者。

核心结论

  • 2023年MOGAD标准正确识别了大多数MOGAD儿童和成人,在疾病发作期应用时准确率最高。

研究设计与样本

  • 前瞻性观察性全国研究,纳入257例(133例儿童)血清或脑脊液MOG-IgG阳性且伴脱髓鞘综合征或脑炎的患者,中位年龄15岁(四分位距6-38),54%为女性。

主要发现

  • 202例于疾病发作期评估的患者中,158例(78%)血清MOG-IgG高滴度,36例(18%)低滴度,8例(4%)仅脑脊液抗体阳性。
  • 低滴度患者较高滴度患者更易在末次随访时诊断为其他疾病(2/36 [6%] vs 0/158,p=0.012)。
  • 230/257(89%)患者存在支持性特征,与年龄、MOG-IgG滴度和核心综合征无关,但成人视神经炎除外,其眼眶MRI评估未系统进行。
  • 240/257(94%)患者被MOGAD标准正确分类(236例最终为MOGAD,4例为其他诊断),17例分类错误(11例最终为MOGAD,6例为其他诊断)。

关键数值与推荐

  • 2023年MOGAD标准总体正确分类240/257(94%)患者。
  • 发作期阳性预测值99%(95%CI 97-100),缓解期98%(95%CI 89-100)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The 2023 criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) perform well in adults but have not been assessed in children. METHODS: This prospective observational nationwide study includes children and adults with demyelinating syndromes or encephalitis, whose serum or CSF was found MOG-immunoglobulin G (IgG) positive at Institut d'Investigacions Biomèdiques August Pi i Sunyer-Hospital Clínic of Barcelona (Spain). Exclusion criteria were lack of clinical information and follow-up <1 year, and serum unavailable for antibody testing. The primary outcome was to assess the accuracy of the 2023 MOGAD criteria, using as gold standard the most plausible diagnosis after a follow-up >1 year. MOGAD criteria were retrospectively applied assessing core syndromes, supportive clinical-radiological features, and MOG-IgG titers. Patients tested ≤3 months of a disease attack (acute phase) or afterward (remission) were considered separately. The positive predictive value (PPV) of the criteria (true-positive [patients classified as MOGAD and MOGAD diagnosis last follow-up] divided by total positive [all patients classified as MOGAD]), and its 95% CI, was calculated with the Wilson procedure. RESULTS: A total of 257 patients (133 children) were included in the study (median age 15 years [interquartile range 6-38], 54% female). Among 202 patients assessed during a disease attack, 158 (78%) had high MOG-IgG serum titers, 36 (18%) low titers, and 8 (4%) antibodies only in CSF. No differences were identified between patients with high and low titers, but those with low titers were more likely to have an alternative diagnosis at last follow-up (2/36 [6%] vs 0/158, p = 0.012). Supportive features were present in 230 of 257 (89%) patients, regardless of age, MOG-IgG titers, and core syndromes except for optic neuritis in adults whose assessment with orbital MRI was not systematic. Overall, 240 of 257 (94%) patients were well classified by the MOGAD criteria (e.g., 236 eventually having MOGAD and 4 alternative diagnoses), and 17 were wrongly classified (e.g., 11 eventually having MOGAD and 6 alternative diagnoses). Although the criteria classified better during disease attacks than during remissions (187 [96%] vs 49 [89%] serum MOG-IgG-positive patients were well-classified, p = 0.038), the PPV was high in both settings (99% [95% CI 97-100] vs 98% [95% CI 89-100]). DISCUSSION: The 2023 MOGAD criteria correctly identified most children and adults with MOGAD. The highest accuracy occurred when they were applied during disease attacks. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that the 2023 MOGAD criteria accurately identify adults and children with MOGAD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Fonseca E, Olivé-Cirera G, Martinez-Hernandez E, et al. Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks. Neurology. 2024. PMID: 39190859. doi:10.1212/WNL.0000000000209682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。